- Home
- CPRX vs SRRK Comparison
CPRX vs SRRK Comparison
Compare CPRX & SRRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CPRX
- SRRK
- Stock Information
- Founded
- CPRX 2002
- SRRK 2012
- Country
- CPRX United States
- SRRK United States
- Employees
- CPRX N/A
- SRRK N/A
- Industry
- CPRX Biotechnology: Pharmaceutical Preparations
- SRRK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CPRX Health Care
- SRRK Health Care
- Exchange
- CPRX Nasdaq
- SRRK Nasdaq
- Market Cap
- CPRX 2.8B
- SRRK 2.9B
- IPO Year
- CPRX 2006
- SRRK 2018
- Fundamental
- Price
- CPRX $22.52
- SRRK $30.75
- Analyst Decision
- CPRX Strong Buy
- SRRK Strong Buy
- Analyst Count
- CPRX 7
- SRRK 6
- Target Price
- CPRX $32.29
- SRRK $42.17
- AVG Volume (30 Days)
- CPRX 1.7M
- SRRK 1.6M
- Earning Date
- CPRX 05-07-2025
- SRRK 05-06-2025
- Dividend Yield
- CPRX N/A
- SRRK N/A
- EPS Growth
- CPRX 107.94
- SRRK N/A
- EPS
- CPRX 1.31
- SRRK N/A
- Revenue
- CPRX $491,734,000.00
- SRRK N/A
- Revenue This Year
- CPRX $15.17
- SRRK N/A
- Revenue Next Year
- CPRX $9.61
- SRRK $601.05
- P/E Ratio
- CPRX $17.19
- SRRK N/A
- Revenue Growth
- CPRX 23.49
- SRRK N/A
- 52 Week Low
- CPRX $14.47
- SRRK $6.76
- 52 Week High
- CPRX $26.16
- SRRK $46.98
- Technical
- Relative Strength Index (RSI)
- CPRX 48.15
- SRRK 49.04
- Support Level
- CPRX $21.93
- SRRK $28.79
- Resistance Level
- CPRX $23.27
- SRRK $31.09
- Average True Range (ATR)
- CPRX 1.27
- SRRK 2.50
- MACD
- CPRX -0.14
- SRRK 0.44
- Stochastic Oscillator
- CPRX 50.60
- SRRK 78.82
About CPRX Catalyst Pharmaceuticals Inc.
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers three drug products, FIRDAPSE (amifampridine), FYCOMPA (perampanel), and AGAMREE (vamorolone).
About SRRK Scholar Rock Holding Corporation
Scholar Rock Holding Corp is a late-stage biopharmaceutical company focused on discovering, developing, and delivering innovative medicines for treating serious diseases in which signaling by protein growth factors plays a fundamental role. Its pipeline includes Neuromuscular and Obesity, Immuno-oncology, Fibrotic Disease, and Hematology. The group operates and manages its business as a single segment to assess performance and make operating decisions.